Abstract Mutations in the ß-glucocerebrosidase gene (GBA), which encodes the lysosomal enzyme ß-glucocerebrosidase, have traditionally been implicated in Gaucher disease, an autosomal recessive lysosomal storage disorder. Yet the past two decades have yielded an explosion of epidemiological and basic-science evidence linking mutations in GBA with the development of Parkinson disease (PD) as well. Although the specific contribution of mutant GBA to the pathogenesis of parkinsonism remains unknown, evidence suggests that both loss of function and toxic gain of function by abnormal ß-glucocerebrosidase may be important, and implicates a close relationship between ß-glucocerebrosidase and α-synuclein. Furthermore, multiple lines of evidence suggest that although GBA-associated PD closely mimics idiopathic PD (IPD), it may present at a younger age, and is more frequently complicated by cognitive dysfunction. Understanding the clinical association between GBA and PD, and the relationship between ß-glucocerebrosidase and α-synuclein, may enhance understanding of the pathogenesis of IPD, improve prognostication and treatment of GBA carriers with parkinsonism, and furthermore inform therapies for IPD not due to GBA mutations.
(DLB) [9] . The effect of a GBA mutation may be mutationspecific: for example, "mild" GBA mutations confer about twice the risk of developing parkinsonism to carriers compared with noncarriers, whereas "severe" mutations confer up to 13 times the risk [10] . Furthermore, unlike other PD-related genes such as LRRK2 and the α-synuclein gene SNCA, which are viewed as causal (albeit with reduced penetrance), there is debate as to whether GBA mutations as a group should be considered dominant causal genes or susceptibility mutations [11] . Ultimately, they may represent both, and it may be most accurate to consider the mutations as "causal but complex," falling outside the simple Mendelian paradigm (see Fig. 1 ).
Understanding the clinical and genetic issues surrounding GBA-related parkinsonism informs clinical care, including genetic counseling, and research. In this review, we will explore the background, pathophysiology, pathology, and clinical implications of the complex relationship between GBA mutations and parkinsonism, including a putative role for ß-glucocerebrosidase in IPD as well.
The Evidence Linking GBA and Parkinsonism

Parkinsonism in GD Patients
In the 1990s, reports on patients with GD1 who also had concomitant parkinsonism emerged. Neudorfer et al. [3] described six patients with otherwise classic GD1 who developed parkinsonism at a mean age of 49 years, and who presented with atypical features: two had severe psychiatric symptoms, including depression and psychosis; one had myoclonus; and four were unresponsive to levodopa therapy. Tayebi et al. [12] described a woman with mild GD1 due to compound heterozygosity for the GBA mutations L444P and D406H who developed left-hand tremor at age 42 years, followed by progressive left-sided rigidity and gait deterioration, and atypical features such as supranuclear ophthalmoplegia, retrocollis, myoclonus, upper motor neuron signs, and progressive confusion. A later series described additional GD1 patients with atypical parkinsonism beginning in their 40s, a third of whom had dementia, and two of whom had slowed horizontal saccadic eye movements [13] . Yet the apparent pattern of atypical parkinsonism in GD1 patients was not universal and a report followed of four GD1 patients with a more typical, levodopa-responsive PD phenotype [14] . More recent assessments of large GD cohorts have underscored the high susceptibility for PD among patients with GD1, estimating the lifetime relative risk of developing PD among GD1 patients to be 21.4 times that of the general population [15] , and the probability that a GD1 patient will develop parkinsonism to be 5-7 % before age 70 years, and 9-12 % before age 80 years [16] . Most PD-related genes have fairly clear autosomal dominant (LRRK2) or autosomal recessive (ATP13A2, DJ1) inheritance. Certain genes (parkin, PINK1) are largely autosomal recessive, although disease may be present in the heterozygous state. GBA is even more complex genetically: "mild" mutations could be considered as risk factors for PD or as autosomal dominant PD genes with a low penetrance; "severe" mutations could be considered as either stronger risk factors for PD or autosomal dominant PD genes with a higher penetrance; and heterozygosity for two GBA mutations results in Gaucher disease, type 1 (GD1) of which carries an increased risk of developing PD. The relationship of GBA mutations to PD thus confounds the classical paradigm of monogenic disorders Pathological Evidence Postmortem microscopic examination of the brains of GD1 patients with parkinsonism has demonstrated substantia nigra neuronal Lewy bodies and loss of pigmented neurons, similar to IPD [13] . Lewy bodies have also been found in hippocampal pyramidal cell layers CA2-CA4 in the brains of GD1 patients with parkinsonism [17] , and these cell layers are selectively involved in only a few other conditions, including, notably, DLB [17] . In addition, GD1 patients without parkinsonism displayed astrogliosis in these hippocampal layers, suggesting that some aspect of GD pathophysiology selectively targets these cells, and that their involvement is likely not due to coincident DLB or IPD [17] . Further, α-synuclein oligomers similar to those seen in synucleinopathies such as advanced IPD and DLB are also observed in cortical tissue of GBA heterozygotes with parkinsonism and GD1 [9] ; however, it is debated whether GBA-related parkinsonism results in a higher burden of Lewy body disease than IPD [18] .
Parkinsonism in GD Families and GBA Heterozygotes; GBA
Mutations in PD Clinics
The high prevalence of parkinsonism among obligate GBA carriers [19] led to a search for GBA mutations among IPD patients. Analysis of 57 subjects with pathologically confirmed IPD found that 21 % harbored a GBA mutation [20] . Among Ashkenazi Jewish patients with PD, 31.3 % were found to carry GBA mutations, as opposed to 6.2 % of controls [21] . The percentage of GBA mutation carriers was found to be slightly lower in other Ashkenazi Jewish PD cohorts, but the association between GBA and IPD in Ashkenazim remains robust [10, 22] . Although it was initially unclear whether GBA mutations conferred an epidemiologically significant risk of IPD in other ethnic populations, the association between GBA mutations and IPD has been confirmed worldwide [23, 24] , although the predominant mutations and the magnitude of the epidemiological risk vary from population to population [5, 6, 7•, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] .
GBA-Associated PD: Is There a Distinct Phenotype Nested Within a Wide Phenotypic Spectrum?
Early reports of GD1 patients with parkinsonism described a range of phenotypes, from a classic IPD picture, to the atypical presentations described in the previous sections [3, 12, 13] . Although GBA-associated PD is often indistinguishable from IPD, emerging research suggests there are subtle differences (see Table 1 ). One small study showed no difference between GBA-associated PD and IPD patients in age of onset, risk of dementia, levodopa responsiveness, or prevalence of different parkinsonian motor signs at initial evaluation [40] , but GBAassociated PD patients were more likely to have symmetrical onset of motor manifestations (27.5 %, vs 8.1 % in IPD), and were slightly less likely to present with tremor (70.3 %, vs 86.5 % in IPD patients). A larger study found GBA-associated PD patients were more likely than IPD and LRRK2-associated PD patients to present initially with bradykinesia [41] , an observation that was replicated in a large European study [7• ]. Yet other studies have not clearly identified motor differences between IPD and GBA-associated PD patients [22] .
Whether GBA mutations affect the age of onset of PD remains disputed. Some studies have found that GBA mutations result in a later age of onset [32] or have no impact [7•, 29] , but most demonstrate an earlier onset of PD symptoms in mutant GBA carriers [25, 27, 35, 36, 38, 42] . One group found that the mean age of symptom onset in GBA and LRRK2 carriers is younger than in IPD (55 and 57 years, respectively, vs 61 years) [10] , and that the percentage with early onset (i.e., onset before 50 years of age) is higher in GBA-associated PD (19 %, vs 15 % in noncarriers) [41] . Although many studies suggest that GBA carriers are slightly younger at onset, and that they may be overrepresented in early-onset groups [22] , in most studies, the average age of onset of GBA-associated PD remains between 50 and 60 years. The severity of GBA mutations may impact on the age of PD onset at well (see later).
Impaired Cognition
Although GBA-associated PD as a whole, including GBAassociated PD and GD1-associated PD, does not usually present with predominant cognitive dysfunction, the most prominent atypical subgroup of GBA-associated PD resembles DLB with early cognitive impairment, or PD with dementia. The possibility that GBA mutations might confer a greater burden of cognitive impairment was suggested by the finding of hippocampal gliosis and Lewy bodies in GD1 patients [17] and by a study of GBA-associated PD heterozygotes, two thirds of whom had varying degrees of cortical and hippocampal Lewy bodies [20] . In a group of PD patients who were first diagnosed with GD1 after genetic screening for research, we reported a phenotype with prominent development of cognitive impairment and cognitive fluctuations, variably complicated by depression, anxiety, and a propensity for medication-induced hallucinations [4] . GBA mutations have also been implicated in DLB. In one study of autopsied brains with synucleinopathies, 23 % of DLB subjects carried GBA mutations [43] . A later neuropathology study found that 28 % of DLB brains had GBA mutations, compared with 10 % of Alzheimer disease brains, and 1 % of controls. Furthermore, the presence of a GBA mutation was associated with a greater likelihood of having cortical Lewy bodies [44] . A large clinical study looked for the presence of N370S and L444P mutant GBA alleles in PD patients, healthy controls, and DLB patients, and found GBA mutations were more than six times as frequent in PD and DLB cohorts compared with controls [45] .
A retrospective study of PD patients found cognitive impairment, including dementia, in 48 % of GBA carriers, as well as a higher burden of cortical Lewy body disease [5] . GBA-associated PD patients are more likely than IPD patients to report subjective cognitive impairment as screened in part I of the Unified Parkinson's Disease Rating Scale [46] , and a handful of studies have demonstrated clear objective cognitive impairment in GBA-associated PD. One study showed that GBA-associated PD patients score lower than IPD patients on the Montreal Cognitive Assessment [47•] . Another found that GBA-associated PD patients perform significantly worse on visuospatial and memory tasks, particularly nonverbal memory tasks, compared with IPD patients, and are more likely to meet the criteria for mild cognitive impairment or dementia than IPD [8•]. Indeed, mutations in GBA confer a sixfold increased risk of developing dementia during the course of PD [48•] .
Despite all these findings, research may be biased away from detecting cognitive impairment in GBA-associated PD, as recruitment comes from source populations with a focus on PD, not parkinsonism more generally. A small study of patients with parkinsonism and GBA mutations found a wide range of clinical manifestations, from an akinetic type of PD to a clinical picture similar to that of DLB [49] , raising the question of whether studies of GBA mutations should seek to broaden the enrollment criteria, as prominent early cognitive features may preclude inclusion in PD studies.
Hallucinations, Apathy, Anxiety, and Depression
The burden of depression and other neuropsychiatric symptoms such as apathy, anxiety, and sleep disruption may be greater in GBA-associated PD [47•] . In GD1 patients with PD, we found that visual hallucinations were a complication of therapy in all subjects [4] . Others found that 45 % of GBAassociated PD subjects developed visual hallucinations not related to treatment, on average about 10 years after motor symptom onset [5] . Another recent study found that although GBA-associated PD patients are as likely as IPD patients to experience hallucinations at least once during the course of their disease, they are much more likely to experience persistent hallucinations, with 26.5 % of GBA carriers having hallucinations for more than 6 months, compared with only 6.7 % of noncarriers [50] . . Dysautonomia also appears to be part of the phenotypic spectrum of GBA-associated parkinsonism [46] .
Neuroimaging in GBA-Associated PD
Transcranial Sonography
Transcranial sonography is a relatively inexpensive modality that demonstrates hyperechogenicity of the substantia nigra in approximately 90 % of PD patients and 10-15 % of controls [51] . Nigral hyperechogenicity is observed in GD1 patients with PD, and is similar to that seen in DLB, IPD, and PD with dementia [4] . It is also seen in heterozygous GBA carriers with PD [46, 52] , and gene dose (one vs two GBA mutations) does not affect the degree of nigral echogenicity [52] . Transcranial sonography images in GD1 patients without PD are normal [53] . Hypoechogenicity of the brainstem raphe, reported in PD with depression [51] , may reflect structural damage to the serotonergic system, and is more prevalent in PD patients with GBA mutations than in IPD patients [46, 53] and controls [53] , and may correspond to the increased rate of depression among GBA-associated PD patients [46] .
Functional Neuroimaging
Positron emission tomography (PET) using several different radioisotopes has been used to interrogate brain function and metabolism in GBA-associated parkinsonism. [
11 C]2β-carbomethoxy-3β-(4-fluorophenyl)tropane PET has demonstrated decreased uptake suggestive of presynaptic dopaminergic dysfunction in GBA heterozygotes and homozygotes with parkinsonism [54, 55] , but normal uptake in asymptomatic GBA carriers [54] . 18 F-fluorodopa PET, which evaluates presynaptic dopamine terminals, has demonstrated reduced 18 F-fluorodopa uptake in the striatum of GD1 patients [4, 56] and GBA-associated PD heterozygotes [52] , similar to what is found in IPD. Fluorodeoxyglucose PET has shown hypermetabolism in the lentiform nuclei in GD1-associated PD patients, similar to what is found in IPD [4] . Fluorodeoxyglucose PET has also demonstrated cortical hypometabolism of differing degrees in the parietal, parietooccipital, and temporal lobes in both GD1-associated PD patients [4] and GBA-associated PD patients [52] , correlating with the cognitive impairments seen in these subjects. One recent study [57] demonstrated that GD1-associated PD patients and IPD patients had comparably diminished striatal 18 Ffluorodopa uptake on 18 F-fluorodopa PET, but that GD1-associated PD patients also had diminished resting regional blood flow in the parieto-occipital and precuneal cortices as visualized by H 2 15 O PET. This latter finding is similar to that seen in DLB, and underscores the cortical involvement in GD1 patients with PD [57] .
Risk of PD Associated with GBA Mutations, and the Relation Between Mutation Type and Risk and Severity of PD
On the expanding list of hundreds of GBA mutations and polymorphisms, the N370S and L444P mutations are among the commonest in those of Ashkenazi Jewish descent [2] , and are most frequently studied across all ethnic groups. GBA mutations range from "mild" mutations such as N370S, which results in slightly diminished ß-glucocerebrosidase activity, to mutations causing a severely dysfunctional enzyme, or null mutations resulting in no protein production at all [2] . The severity of mutation may modify the risk of developing parkinsonism, with mild mutations such as N370S and R496H conferring about twice the risk of disease compared with the risk for noncarriers, but severe mutations (including 84GG, IVS2+1, V394L, D409H, L444P, and RecTL) conferring over 13 times the risk [10] . Mutation type may affect the age of onset, with patients carrying severer GBA mutations having an average age of onset 2 years earlier than those with mild mutations [10] . Some researchers have also found that among carriers of severe mutations, those with null or complex mutations had an earlier age of onset than those with missense mutations 7 , and had increased risk of developing parkinsonism [58] . It has also been suggested that there is a dose effect related to carrying two mutant alleles, as GBA homozygotes or compound heterozygotes have an average age of onset 9.5 years younger than noncarriers [10] , and GD1 patients with parkinsonism frequently develop motor symptom onset before age 50 years [3, 12, 14] . As in other complex genetic disorders with reduced penetrance, additional genetic factors and environmental modifiers are being sought. This discussion of genotypephenotype correspondence and variable penetrance has significant genetic counseling implications among heterozygote carriers with PD, as the relative risk to offspring is very different depending on the mutation.
Pathogenesis of GBA-Associated PD, and Its Implications for Treatment
The process by which GBA mutations promote neurodegeneration and parkinsonism is still being determined. An excellent recent review by Westbroek et al [59•] . summarizes much of the evidence linking GBA to PD pathogenesis, including data to support hypotheses both of a loss of ß-glucocerebrosidase function and of a gain of toxic function by the abnormal enzyme, either of which could mediate α-synuclein accumulation. Most recently Mazzulli et al [60••] . have proposed a bidirectional loop whereby abnormal ß-glucocerebrosidase promotes α-synuclein accumulation, and α-synuclein impairs ß-glucocerebrosidase function, leading to subsequent neurodegeneration.
Genotype-phenotype correlations lend some support to the loss-of-function hypothesis, as null mutations of GBA, which result in the absence of a protein, significantly increase the risk of developing parkinsonism, and correlate with an earlier age of disease onset [10, 58] . Multiple regions in GBA-associated PD brains, including substantia nigra, putamen, cerebellum, and amygdala, have reduced levels of ß-glucocerebrosidase protein and activity, unrelated to cell loss from neurodegeneration [61•] . Brains of IPD subjects without GBA mutations also demonstrate reduced enzyme levels and activity in the substantia nigra and cerebellum (although to a lesser degree than in GBA-associated PD subjects) [61•] , and it has been posited that there is a downstream role of ß-glucocerebrosidase in non-GBA PD as well, likely due to accumulation of α-synuclein, and possibly due to oxidative stress and mitochondrial dysfunction. This has furthered theories that lysosomal enzyme dysfunction in general contributes to IPD pathogenesis, as there are reduced levels of multiple lysosomal enzymes in the cerebrospinal fluid of IPD subjects, including not only ß-glucocerebrosidase, but also α-mannosidase, ß-mannosidase, and ß-hexosaminidase [62] .
Multiple emerging lines of evidence point to an important relationship between ß-glucocerebrosidase and α-synuclein. Mutant ß-glucocerebrosidase and α-synuclein interact with each other at lysosomal pH [63] ; and in cell models mutant ß-glucocerebrosidase promotes the accumulation of α-synuclein [64•] . ß-Glucocerebrosidase is present, along with α-synuclein, in an average of 75 % of the Lewy bodies in the brains of GBA-associated PD subjects, but is a component of less than 10 % of Lewy bodies in noncarrier PD subjects [65] . In the feedback loop model, glucocerebroside, a substrate of ß-glucocerebrosidase, may promote stabilization of α-synuclein into oligomers similar to those found in Lewy bodies, and mutations in ß-glucocerebrosidase correspondingly lead to α-synuclein accumulation; at the same time, α-synuclein impairs ß-glucocerebrosidase function within lysosomes, both in PD cells and in normal cells, promoting further accumulation of glucocerebroside [60••] .
Significant evidence also supports a gain of toxic function by mutant ß-glucocerebrosidase as an explanation for GBAassociated PD, although this is hard to reconcile with the fact that null mutations are also associated with PD. Mutant ß-glucocerebrosidase may disrupt a neuron's machinery for eliminating abnormally folded proteins, not only through lysosomal dysfunction, but also by impairing the endoplasmic-reticulumassociated degradation (ERAD) of proteins. Parkin, a ubiquitin E3 ligase involved in ERAD, aggregates with mutant ß-glucocerebrosidase, and stabilizes it rather than mediating its degradation [66] . By aggregating with parkin, mutant ß-glucocerebrosidase may impair parkin's activity, resulting in an accumulation of its misfolded protein substrates, which are cytotoxic [66] .
Magnetic resonance spectroscopy [67] has revealed some unique aspects of GBA-associated PD pathophysiology. It has demonstrated normal levels of high-energy phosphates [67] , supporting the idea that mitochondrial dysfunction is not a major contributor to GBA-associated PD [59•].
Magnetic resonance spectroscopy has also demonstrated elevated levels of certain unusual membrane degradation products in GBA-associated PD [67] , which may reflect altered brain lipid metabolism. The finding that GBA-associated PD subjects have lower cerebrospinal fluid concentrations of total fatty acids and numerous specific fatty acids compared to IPD subjects [68] also implicates abnormal brain lipid metabolism in the pathogenesis of GBA-associated PD.
Treatment of GBA-Associated PD: PD-Focused Therapies
To date, no large-scale studies have specifically addressed the relative benefits and risks of different treatments for GBA-associated PD compared with IPD. Thus, treatment of GBA-associated PD currently follows the same principles as treatment of IPD, addressing motor, cognitive, and neuropsychiatric manifestations as needed.
Early reports of GD1-associated parkinsonism described a levodopa-resistant disease [12, 13] , but others have reported more typical-appearing, levodopa-responsive patients [14] . One large study of mutant GBA heterozygotes with PD discovered that about 90 % of them had a favorable, enduring response to levodopa; the remainder ranged from initially responsive with subsequently diminished benefit, to completely unresponsive [5] . Another large study found a slightly but significantly greater burden of levodopa-induced dyskinesias among GBA-associated PD patients (62 %) compared with IPD patients (50 %), independent of levodopa dose and the duration of treatment or disease [7•].
Although neuropsychiatric and cognitive disturbances significantly burden GBA-associated PD patients, little is known about whether such disturbances require different treatment in GBA-associated PD patients compared with IPD patients. That said, in a retrospective investigation of neuropsychiatric comorbidities and their treatment in GBAassociated PD patients and noncarriers, Barrett et al [50] . found that 41 % of GBA carriers were treated with an acetylcholinesterase inhibitor, compared with 15 % of noncarriers; the rate of antipsychotic use was not significantly different.
There are also limited data to guide decisions about surgical management of GBA-associated PD, with most of our understanding coming from isolated case descriptions. Pallidotomy may [69] or may not [12] be beneficial, and some patients have improved with bilateral subthalamic nucleus deep brain stimulation [7•]. Whether GBA-associated PD requires a particular surgical approach should be the subject of more systematic investigation.
Treatment of GBA-Associated PD: GD-Focused Therapies Enzyme replacement therapy revolutionized the treatment of GD1 patients in the 1990s, significantly reducing morbidity from the bone, blood, and visceral manifestations of the disease. Early reports of GD1 patients with parkinsonism were quick to note that neurological symptoms did not improve with enzyme replacement [12] [13] [14] . A later case report showed that miglustat, which treats GD1 by lowering elevated levels of substrates of glucocerbrosidase, was tolerated by a patient with GD1 and parkinsonism [70] , although the suggestion that miglustat might have stabilized his neurological condition caused some contention [71] , as miglustat does not readily cross the blood-brain barrier. Recently, investigation in mouse models of GD1-associated PD found that viral-vectormediated replacement of normal GBA genes in the CNS resulted in expression of normal ß-glucocerebrosidase in brain tissue, improvement in memory function when the virus was delivered to the hippocampus, and slowing of the rate of α-synuclein accumulation compared with mice given a control virus [72] . Furthermore, administration of normal GBA to mice with wild-type GBA alleles but excessive α-synuclein expression enhanced ß-glucocerebrosidase activity, and led to a reduction in the level of soluble α-synuclein (with a trend toward reduction in the level of membrane-bound α-synuclein, and no change in the level of insoluble α-synuclein) [72] . These findings suggest the intriguing possibility that targeted ß-glucocerebrosidase replacement in the CNS could slow, stabilize, or reverse some of the neurological manifestations in GBA-associated PD. Furthermore, because ß-glucocerebrosidase activity has been shown to be decreased in the substantia nigra of IPD brains without GBA mutations [61•] , some have conjectured that therapies modulating ß-glucocerebrosidase might impact on IPD as well [72, 73] .
Implications for Genetic Counseling
The implications of the connection between GBA and PD remain ambiguous for families carrying GBA mutations. Although most patients with GD1 never develop parkinsonism [59•] , mutant GBA is considered a susceptibility gene that increases the risk of developing PD, and GBA mutations are highly prevalent among PD patients. As noted, GBA mutations have a heterogeneous effect on PD risk, with severer mutations being associated with a higher rate of disease than milder ones. Under an autosomal dominant model, penetrance has been estimated to be 7.6 % at 50 years, 13.7 % at 60 years, 21.4 % at 70 years, and 29.7 % at 80 years [74•] , although it may be inaccurate to consider GBAassociated PD as autosomal dominant [75] (see Fig. 1 ). Although knowledge of gene status does not currently impact management of heterozygotes, if homozygotes or compound heterozygotes are identified, they should be referred for evaluation of the bone and other organ manifestations of GD.
Conclusion
The observation that homozygotes and heterozygotes for GBA mutations are at increased risk of developing parkinsonism and IPD has led to an explosion of research into the natural history and pathogenesis of GBA-associated PD. This has prompted new approaches to understanding IPD more broadly, and to deciphering the underlying molecular biology of GBA-associated PD, with the ultimate goal of optimizing treatment for this subgroup of IPD patients. Future work will need to determine whether GBA-associated PD patients benefit from different therapies than IPD patients, and will need to develop treatments that target the unique pathophysiology of this PD variant. In the end, genetic testing may one day be able to identify patients who would benefit from specific, personalized treatments. Further, discoveries made through investigations into GBA-associated PD may ultimately lead to enhanced treatment for all patients with PD. In this study, the investigators sought to define the cognitive profile of GBAassociated PD, building on prior findings of increased risk of cognitive impairment in GBA carriers compared with noncarriers. They used the widely available and easily administered Mini Mental State Examination, as well as a more comprehensive neuropsychological battery. They found that although GBA carriers did not differ from noncarriers in terms of demographics, olfactory function, and motor severity, they had worse performance on multiple cognitive tasks, including the Mini Mental State Examination, and memory and visuospatial tasks. Most prominently, they had significant difficulty in the nonverbal memory domain. These findings underscore the fact that GBA-associated PD carries the risk of general cognitive impairment, with enhanced vulnerability in particular cognitive domains.
